The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets...
The European Research Council (ERC) grants are among the most prestigious awards in the scientific community. Prof Anna Hirsch from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now succeeded...
NFDI4Microbiota is set to become part of Germany’s national research data infrastructure (NFDI). In May 2021, a panel of experts recommended that the consortium should receive NFDI funding – and now the Joint Science...
How can we apply the knowledge we have gained so far to better overcome the current crisis and prevent another pandemic in future? Helmholtz aims to find answers to these questions with two new, interdisciplinary...
Increasingly insensitive to standard drugs: Multi-resistant pathogens are spreading worldwide and even in the near future could threaten the safe treatment of deadly infectious diseases. However, the urgent demand for...
The Alexander von Humboldt Foundation has selected Prof Claus-Michael Lehr as a scout within the Henriette Herz Programme.This award allows him to select three young scientific talents from abroad who will work at HIPS...
Dr Chantal Bader, postdoc in the Department of Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), has been awarded a grant from the Hans-and-Ruth-Giessen-Foundation on 29...
The human recombinant anti-SARS-CoV-2 antibody COR-101 was developed in close cooperation of Technische Universität Braunschweig, the Helmholtz Centre for Infection Research (HZI) and the biotech company YUMAB GmbH in...
Am I infected with SARS-CoV-2? Is it one of the dangerous variants? Being able to answer these and more questions with a single efficient diagnostic test can be decisive for gauging the spread of disease and selecting...
